Rice bioengineers develop protein-based shield for insulin-producing cells

The breakthrough, published in Science Advances, addresses the primary obstacle in cell-based therapies: immune rejection. Typically, the body identifies foreign implants and seals them off with scarlike tissue, a process known as fibrosis that eventually suffocates the cells. By co-packaging IL-10-producing cells with insulin-producing ones inside hydrogel capsules, the researchers found they could suppress this localized immune response without the need for systemic immunosuppressants.

Dilrasbonu Vohidova, a doctoral student in bioengineering and co-first author of the study, emphasized that avoiding systemic drugs is vital to reducing risks of infection and organ failure. The team’s laboratory tests showed IL-10 was the most effective cytokine for maintaining immune balance. Subsequent trials in nonhuman primates confirmed the implants continued to produce the protective protein without triggering harmful side effects elsewhere in the body.

Omid Veiseh, a Rice bioengineer and director of the Rice Biotech Launch Pad, described the platform as a "living pharmacy" that works in harmony with the host immune system. While the research remains in the preclinical stage, the team is working toward clinical trials. Beyond Type 1 diabetes, this strategy holds potential for treating various autoimmune diseases and improving outcomes for organ transplantation.